- Home
- GEG vs ATNM Comparison
GEG vs ATNM Comparison
Compare GEG & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- ATNM
- Stock Information
- Founded
- GEG 1994
- ATNM 2000
- Country
- GEG United States
- ATNM United States
- Employees
- GEG N/A
- ATNM N/A
- Industry
- GEG Computer Software: Prepackaged Software
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- GEG Technology
- ATNM Health Care
- Exchange
- GEG Nasdaq
- ATNM Nasdaq
- Market Cap
- GEG 54.1M
- ATNM 46.5M
- IPO Year
- GEG N/A
- ATNM N/A
- Fundamental
- Price
- GEG $1.91
- ATNM $1.30
- Analyst Decision
- GEG
- ATNM Strong Buy
- Analyst Count
- GEG 0
- ATNM 4
- Target Price
- GEG N/A
- ATNM $8.75
- AVG Volume (30 Days)
- GEG 13.6K
- ATNM 406.4K
- Earning Date
- GEG 05-07-2025
- ATNM 05-06-2025
- Dividend Yield
- GEG N/A
- ATNM N/A
- EPS Growth
- GEG N/A
- ATNM N/A
- EPS
- GEG 0.00
- ATNM N/A
- Revenue
- GEG $19,204,000.00
- ATNM N/A
- Revenue This Year
- GEG N/A
- ATNM N/A
- Revenue Next Year
- GEG N/A
- ATNM N/A
- P/E Ratio
- GEG $17,949.65
- ATNM N/A
- Revenue Growth
- GEG 73.75
- ATNM N/A
- 52 Week Low
- GEG $1.70
- ATNM $1.03
- 52 Week High
- GEG $2.04
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- GEG 52.22
- ATNM 48.90
- Support Level
- GEG $1.76
- ATNM $1.17
- Resistance Level
- GEG $1.95
- ATNM $1.45
- Average True Range (ATR)
- GEG 0.06
- ATNM 0.13
- MACD
- GEG 0.00
- ATNM -0.01
- Stochastic Oscillator
- GEG 57.69
- ATNM 51.56
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.